paracentesis

PROCEDURE13 trials

Sponsors

Neovii Biotech, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, University Hospital, Ghent, Siriraj Hospital, Abramson Cancer Center at Penn Medicine

Conditions

Acute Myeloid LeukemiaAnatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8AscitesClinical Stage IV Esophageal Adenocarcinoma AJCC v8Clinical Stage IV Gastric Cancer AJCC v8Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8Critically Ill

Phase 2

Study in EpCAM Positive Patients With Symptomatic Malignant Ascites Using Removab Versus an Untreated Control Group

CompletedNCT00836654

Neovii BiotechEpCam Positive Tumor (e.g.Ovarian, Gastric, Colon, Breast), Malignant Ascites

Start: 2004-09-30End: 2006-11-30Updated: 2009-02-05

Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer

RecruitingNCT05998135

Emory UniversityOvarian High Grade Serous Adenocarcinoma, Platinum-Resistant Ovarian Carcinoma

Start: 2023-11-09End: 2027-06-30Target: 28Updated: 2025-09-11

Treat Malignant Ascites Caused by Gastrointestinal or Ovarian Cancer With M701 Bispecific Antibody

CompletedNCT06266091

Wuhan YZY Biopharma Co., Ltd.Malignant Ascites

Start: 2021-11-24End: 2024-08-01Updated: 2025-07-20

Phase 3

Treatment of Malignant Ascites Caused by Advanced Epithelial Solid Tumors With M701 Bispecific Antibody

Active, not recruitingNCT06432296

Wuhan YZY Biopharma Co., Ltd.Malignant Ascites

Start: 2024-03-20End: 2026-01-30Updated: 2025-07-20

Unknown Phase

An Early Safety and Efficacy Study of Ascites Management: Standard Paracentesis or Early Intervention With Pleurx Catheters in Patients With Malignant Ascites

TerminatedNCT01077063

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsMalignant Ascites

Start: 2010-02-28End: 2013-08-31Updated: 2015-10-29

The Influence of Paracentesis on Intra-abdominal Pressure and Kidney Function in Critically Ill Patients With Liver Cirrhosis and Ascites: an Observational Study

WithdrawnNCT01091233

University Hospital, GhentAscites, Critically Ill, Liver Cirrhosis

Start: 2010-03-31End: 2012-12-31Updated: 2021-07-08

Immediate Anterior Chamber Paracentesis With A 30-Gauge Needle for Acute Primary Angle - Closure

CompletedNCT01923454

Siriraj HospitalGlaucoma, Angle-closure

Start: 2005-12-31End: 2007-06-30Updated: 2013-08-15

Palliative Care Outcomes in the Management of Malignant Ascites by Interventional Radiology

WithdrawnNCT02477657

Abramson Cancer Center at Penn MedicineRefractory Malignant Ascites

Start: 2021-07-31End: 2023-07-31Updated: 2022-01-12

Asymptomatic Spontaneous Bacterial Peritonitis in Patients With Decompensated Liver Cirrhosis

CompletedNCT03163745

Assiut UniversitySpontaneous Bacterial Peritonitis

Start: 2019-03-11End: 2020-05-26Updated: 2020-11-19

Early Use of TIPS With Polytetrafluoroethylene(PTFE) Covered Stents in Cirrhotic Patients With Refractory Ascites

Air Force Military Medical University, ChinaLiver Cirrhoses

Start: 2017-06-29End: 2024-12-31Target: 180Updated: 2022-10-25

Malignant Ascites in Ovarian Cancer: Impact of Total Paracentesis on Hemodynamics

CompletedNCT04032600

Charite University, Berlin, GermanyHemodynamic Instability, Malignant Ascites, Ovarian Cancer

Start: 2017-08-01End: 2019-09-09Updated: 2020-12-08

National Cancer Institute "Cancer Moonshot Biobank"

Active, not recruitingNCT04314401

National Cancer Institute (NCI)Acute Myeloid Leukemia, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8 +26

Start: 2020-11-11End: 2027-04-30Target: 1600Updated: 2026-04-03

Comparison of Crystalloid and Colloid I.V Fluid Therapy in Prevention of Paracentesis Induced Circulatory Dysfunction (PICD) and Renal Dysfunction in Patients With Decompensated Liver Cirrhosis in Egypt: a Randomized Piolet Study

Shady Ashraf KassemAscites

Start: 2023-01-11End: 2024-02-11Target: 60Updated: 2022-02-02

Related Papers

Repurposing atovaquone as a STAT3 inhibitor for the treatment of platinum resistant ovarian cancer.

Journal of Clinical Oncology2024-06-011 citations

The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial.

2010-11-01363 citations